Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial

IMPORTANCE: Studies of neoadjuvant chemotherapy regimens using anthracyclines followed by taxanes have reported a doubling of pathological complete remission (pCR) rates compared with anthracycline-based regimens alone. A reverse sequence did not reduce activity. Nab-paclitaxel is an albumin-bound n...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Gianni, Luca, Mansutti, Mauro, Anton, Antonio, Calvo, Lourdes, Bisagni, Giancarlo, Bermejo, Begoña, Semiglazov, Vladimir, Thill, Marc, Chacon, Jose Ignacio, Chan, Arlene, Morales, Serafin, Alvarez, Isabel, Plazaola, Arrate, Zambetti, Milvia, Redfern, Andrew D., Dittrich, Christian, Dent, Rebecca Alexandra, Magazzù, Domenico, De Fato, Raffaella, Valagussa, Pinuccia, Tusquets, Ignacio
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885830/
https://ncbi.nlm.nih.gov/pubmed/29327055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.4612
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados